Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG. Malet I, et al. Among authors: sayon s. J Antimicrob Chemother. 2011 Dec;66(12):2827-30. doi: 10.1093/jac/dkr389. Epub 2011 Sep 19. J Antimicrob Chemother. 2011. PMID: 21933786
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF. Delelis O, et al. Among authors: sayon s. Antimicrob Agents Chemother. 2010 Jan;54(1):491-501. doi: 10.1128/AAC.01075-09. Epub 2009 Nov 9. Antimicrob Agents Chemother. 2010. PMID: 19901095 Free PMC article.
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, Sayon S, Katlama C, Perno CF, Calvez V, Marcelin AG, Ceccherini-Silberstein F. Malet I, et al. Among authors: sayon s. J Antimicrob Chemother. 2011 Jul;66(7):1481-3. doi: 10.1093/jac/dkr152. Epub 2011 Apr 7. J Antimicrob Chemother. 2011. PMID: 21474479 Free article.
Risk factors for raltegravir resistance development in clinical practice.
Malet I, Fourati S, Morand-Joubert L, Flandre P, Wirden M, Haim-Boukobza S, Sayon S, Pattery T, Simon A, Katlama C, Girard PM, Calvez V, Marcelin AG. Malet I, et al. Among authors: sayon s. J Antimicrob Chemother. 2012 Oct;67(10):2494-500. doi: 10.1093/jac/dks254. Epub 2012 Jul 4. J Antimicrob Chemother. 2012. PMID: 22763565
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.
Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, Sayon S, Pakianather S, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG. Lambert-Niclot S, et al. Among authors: sayon s. PLoS One. 2012;7(7):e41390. doi: 10.1371/journal.pone.0041390. Epub 2012 Jul 25. PLoS One. 2012. PMID: 22848481 Free PMC article. Clinical Trial.
46 results